Navigation Links
Collegium Pharmaceutical Announces Relocation to Massachusetts
Date:1/17/2013

CANTON, Mass., Jan. 17, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain, today announced the relocation of its corporate offices and laboratory facilities to Canton, Massachusetts from Cumberland, Rhode Island.

The Company's lead development program is Oxycodone DETERx® (COL-003), a tamper-resistant, extended-release oxycodone product utilizing its proprietary DETERx® technology. The Oxycodone DETERx® formulation was specifically designed to provide and preserve extended release of the active ingredient following the most common methods of product tampering employed by drug abusers (e.g., crushing, chewing, heating for IV injection, etc.). The product is currently in the final stage of clinical development and has been designated Fast Track Status by the FDA due to its potential to address the problem of prescription drug abuse, a major public health issue in the U.S.

Extended-release formulations of opioids (e.g., OxyContin®) are known to be attractive targets for non-medical use since they contain large doses of drug. Crushing these dosage forms can defeat the extended-release properties and result in immediate availability of the opioid, also known as "dose dumping." Crushed formulations are commonly self-administered by abusers orally, intranasally or by IV injection, resulting in a "high." Although marketed formulations carry labels warning against crushing and breaking, there are reports of legitimate pain patients crushing tablets to facilitate swallowing, a practice that significantly increases their risk of serious adverse events.

"We are pleased to have completed our relocation to Massachusetts. The new analytical and development labs will facilitate the completion of the development of this important product," said Michael Heffernan , CEO of Collegium. "It is becoming increasingly recognized that tamper-resistant, extended-release opioids play an important role in the fight against prescription pain medication abuse. Oxycodone DETERx® may offer a number of significant clinical advantages over currently marketed tamper-resistant opioids for the treatment of chronic pain."

About DETERx® Technology

The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide tamper-resistant properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended-release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx® (COL-003) is the first of a number of product candidates using the DETERx® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique tamper-resistant properties, and flexible dose administration options. For more information, visit the Company's website at www.collegiumpharma.com.

Contact:

Michael Heffernan , President
Collegium Pharmaceutical, Inc.
781-713-3722
mheffernan@collegiumpharma.com


'/>"/>
SOURCE Collegium Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Collegium Pharmaceutical to Present at Piper Jaffrays 24th Annual Healthcare Conference
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
4. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
7. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
8. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
9. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
10. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
11. Icahn Issues Statement Regarding Amylin Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... NASHVILLE, Tenn. , May 26, 2016 ... provider of software and analytics, network solutions ... healthcare, today announced it entered into a ... leading provider of outpatient software solutions and ... surgery centers, specialty hospitals and rehabilitation clinics ...
(Date:5/25/2016)... Germany and GERMANTOWN, Maryland ... (NASDAQ: QGEN ; Frankfurt Prime Standard: QIA) today ... co-development agreement with Therawis Diagnostics GmbH to develop and commercialize ... develop and market PITX2 as a marker to predict effectiveness ... cancer patients. "We are pleased to partner with ...
(Date:5/25/2016)... Va. , May 25, 2016  Granger Diagnostics ... sequencing test for wounds and infections. This test ... parasites, and select viruses. The test requires only ... David G. Bostwick , ... testing to facilitate wound healing: "We are excited ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Aimed at nurses and employees in ... courtesy of leaders in the nursing and health care industry. It also provides ... and associations—namely Jones & Bartlett Learning. , Jones & Bartlett Learning is adding ...
(Date:5/26/2016)... ... 2016 , ... Despite last week’s media reports hinting at a June rate ... until March 2017 for an interest rate increase, according to Rajeev Dhawan of the ... “The Federal Open Market Committee (FOMC) dot charts are of interest to the press ...
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
(Date:5/26/2016)... ... May 26, 2016 , ... The Woodlands at ... offering a new model of care for living and healing, celebrated its grand opening, ... Life in a Real Home provided by Empowered Staff. , “This is an incredibly ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... solutions for drugs, biologics, consumer health and global clinical supply services, today announced ... to support the company’s continued investment and strategic growth plans in the Asia ...
Breaking Medicine News(10 mins):